OncoMatch/Clinical Trials/NCT05882370
TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study
Is NCT05882370 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cadonilimab for hepatocellular carcinoma.
Treatment: Cadonilimab — The purpose of this study is to evaluate the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) plus Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in advanced hepatocellular carcinoma (BCLC-C Stage) accompanied by tumor thrombosis-associated portal hypertension.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC-C (BCLC)
BCLC-C stage accompanied by tumor thrombosis-associated portal hypertension
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: targeted therapy
Newly diagnosed patients who have not received targeted therapy or immunotherapy in the past
Cannot have received: immunotherapy
Newly diagnosed patients who have not received targeted therapy or immunotherapy in the past
Cannot have received: anti-PD-1 therapy
The patient has previously received other anti-PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1
Cannot have received: molecular targeted therapy (apatinib)
or has previously received apatinib therapy
Cannot have received: radiotherapy
Exception: less than 4 weeks before the study medication
Patients who have previously received radiotherapy, chemotherapy, hormone therapy, and surgery, after the completion of the treatment (last medication) and less than 4 weeks before the study medication
Cannot have received: chemotherapy
Exception: less than 4 weeks before the study medication
Patients who have previously received radiotherapy, chemotherapy, hormone therapy, and surgery, after the completion of the treatment (last medication) and less than 4 weeks before the study medication
Cannot have received: hormone therapy
Exception: less than 4 weeks before the study medication
Patients who have previously received radiotherapy, chemotherapy, hormone therapy, and surgery, after the completion of the treatment (last medication) and less than 4 weeks before the study medication
Cannot have received: surgery
Exception: less than 4 weeks before the study medication
Patients who have previously received radiotherapy, chemotherapy, hormone therapy, and surgery, after the completion of the treatment (last medication) and less than 4 weeks before the study medication
Cannot have received: molecular targeted therapy
Exception: less than 5 drug half-lives before the study medication
molecular targeted therapy (including other oral targeted drugs used in clinical trials) is less than the first study medication <5 drug half-lives
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5×10^9/L; Platelet ≥ 50×10^9/L; Hemoglobin ≥ 60 g/L
Kidney function
Serum creatinine ≤ 1.5×ULN
Liver function
Child-Pugh score ≤ 13 points; Bilirubin ≤ 2×ULN; ALT and AST ≤ 5×ULN; Serum albumin ≥ 28 g/L
Cardiac function
QTc ≤ 450ms (male); QTc ≤ 470ms (female); NYHA level <2 heart failure; no unstable angina; no MI within 1 year; no clinically significant arrhythmia requiring intervention
The functions of vital organs meet the following requirements... see inclusion 10 and exclusion 9
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05882370 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior targeted therapy, immunotherapy, anti-PD-1 therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage BCLC-C is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages